A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
CompletedPhase 2Results postedLast updated 19 October 2017
What this trial tests
Phase 2 trial testing BI 409306 100 mg QD in Schizophrenia in 518 participants. Completed in 13 June 2016.
Adults 18 to 55, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline in the Composite Score of Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) After 12 Weeks of TreatmentPrimary· Baseline and Week 12
MCCB comprises 10 tests, which assess 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning problem solving, and social cognition. The composite score was calculated by summing over the standardised score of each domain for analysis and it varies from -20 to 99 with higher score indicating better outcome. The trial was set up as "learn and confirm" model including 2 stages. Stage 1 analysis was conducted to identify the meaningful cognition endpoint(s) (CANTAB domain(s)) and the selected endpoint(s) were to be pre-s
Group
Value
95% CI
BI 409306 - 10 Milligram
1.2
± 0.71
BI 409306 - 25 Milligram
2.7
± 0.74
BI 409306 - 50 Milligram
2.8
± 0.75
BI 409306 - 100 Milligram
1.8
± 0.73
Placebo
2.5
± 0.57
Occurrence of Serious Adverse Events (SAEs) (Including the Abnormalities of Physical Examination, Vital Signs, Electrocardiogram (ECG) Test and Laboratory Tests)Primary· Up to 20 weeks
Occurrence of serious adverse events (SAEs) (including the abnormalities of physical examination, vital signs, electrocardiogram (ECG) test and laboratory tests).
Group
Value
95% CI
BI 409306 - 10 Milligram
0.0
BI 409306 - 25 Milligram
0.0
BI 409306 - 50 Milligram
0.0
BI 409306 - 100 Milligram
0.0
Placebo
5.8
Occurrence of Protocol-specified Adverse Events of Special Interest (AESI)Primary· Up to 20 weeks
Occurrence of Protocol-specified adverse events of special interest (AESI).
Group
Value
95% CI
BI 409306 - 10 Milligram
0.0
BI 409306 - 25 Milligram
0.0
BI 409306 - 50 Milligram
0.0
BI 409306 - 100 Milligram
0.0
Placebo
0.0
Dramatic Worsening of Disease State as Assessed by Positive and Negative Syndrome Scale (PANSS)Primary· Baseline, Week 6 and Week 12
Dramatic worsening of disease state as assessed by Positive and Negative Syndrome Scale (PANSS). It contains 30-items including seven positive symptom items, seven negative symptom items and 16 general psychopathology symptom items. Each item was scored on the same seven point severity scale. Fourteen of the PANSS items required input from an informant. Total score ranges from 30 to 210 (minimum is better). The descriptive statistics of change from baseline (CFB) in PANSS score at week 6 (W6) and week 12 (W12) are presented.
W6-Number of participants analyzed:79,74,67,71,154
Group
Value
95% CI
BI 409306 - 10 Milligram
-0.68
± 6.022
BI 409306 - 25 Milligram
-0.28
± 4.507
BI 409306 - 50 Milligram
-1.09
± 5.415
BI 409306 - 100 Milligram
-1.20
± 5.426
Placebo
-1.81
± 5.895
W12-Number of participant analyzed:83,78,76,81,157
Group
Value
95% CI
BI 409306 - 10 Milligram
-2.59
± 5.342
BI 409306 - 25 Milligram
-0.97
± 5.420
BI 409306 - 50 Milligram
-1.58
± 6.990
BI 409306 - 100 Milligram
-0.94
± 6.315
Placebo
-1.66
± 6.942
Suicidality as Assessed by Columbia Suicidal Severity Rating Scale (C-SSRS)Primary· Up to 12 weeks
C-SSRS: Number (%) of subjects with an event of Suicidal Ideation (Wish to be dead, Non-specific active suicidal thoughts, Active suicidal ideation with any methods (not plan) without intent to act, Active suicidal ideation with some intent to act without specific plan, Active suicidal ideation with specific plan and intent) or Suicidal Behavior (Preparatory acts or behavior, Aborted attempt, Interrupted attempt, Non-fatal suicide attempt, Completed suicide) or Self-injurious behavior without suicidal intent is presented. C-SSRS used only to evaluate whether the patient developed suicidal idea
Group
Value
95% CI
BI 409306 - 10 Milligram
0.0
± 3.677
BI 409306 - 25 Milligram
1.2
± 3.262
BI 409306 - 50 Milligram
2.5
± 3.759
BI 409306 - 100 Milligram
1.2
± 3.497
Placebo
3.6
± 3.954
Change From Baseline in Everyday Functional Capacity as Measured by Schizophrenia Cognition Rating Scale (SCoRS) Global Ratings After 12 Weeks of TreatmentSecondary· Baseline and Week 12
Change from baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) global ratings after 12 weeks of treatment. SCoRS is a 20-item interview-based assessment of cognitive deficits and the degree to which they affect day-to-day functions. Each item was rated on a 4-point scale. Higher ratings reflected a greater degree of impairment. The SCoRS global total scores is the sum of the 20 items and it varies from 20 to 80 with 20 being the best outcome and 80 being the worst. If any individual item was missing, it was imputed with the average of that pati
Group
Value
95% CI
BI 409306 - 10 Milligram
-2.2
± 0.53
BI 409306 - 25 Milligram
-3.1
± 0.56
BI 409306 - 50 Milligram
-2.0
± 0.56
BI 409306 - 100 Milligram
-2.3
± 0.54
Placebo
-2.5
± 0.39
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 12 Weeks of TreatmentSecondary· Baseline and Week 12
Change from baseline in Clinical Global Impressions-Severity (CGI-S) scale score after 12 weeks of treatment. The CGI-S is a one-item evaluation completed by the clinician on the patient's severity of psychopathology. The CGI-S was rated ordinally from one to 7. Higher scores indicate more severe symptoms.
Group
Value
95% CI
BI 409306 - 10 Milligram
-0.1
± 0.05
BI 409306 - 25 Milligram
-0.1
± 0.05
BI 409306 - 50 Milligram
-0.1
± 0.05
BI 409306 - 100 Milligram
-0.1
± 0.05
Placebo
-0.1
± 0.03
Patient Global Impressions-Improvement (PGI-I) Scale Score Measured After 12 Weeks of TreatmentSecondary· Up to 12 weeks
Patient Global Impressions-Improvement (PGI-I) scale score measured after 12 weeks of treatment. The PGI of improvement is a simple evaluation completed by the patient to assess the patient's overall evaluation of his/her status. The PGI of improvement was rated ordinally from one to 7. Higher scores indicate more severe symptoms.
Group
Value
95% CI
BI 409306 - 10 Milligram
2.988
± 1.117
BI 409306 - 25 Milligram
2.883
± 1.124
BI 409306 - 50 Milligram
3.192
± 1.101
BI 409306 - 100 Milligram
3.049
± 1.342
Placebo
3.038
± 1.109
Change in Psychopathology Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS)Secondary· Baseline, Week 6 and Week 12
Change in psychopathology symptoms as assessed by Positive and Negative Syndrome Scale (PANSS). It contains 30-items including seven positive symptom items, seven negative symptom items and 16 general psychopathology symptom items. Each item was scored on the same seven point severity scale. Fourteen of the PANSS items required input from an informant. Total score ranges from 30 to 210 (minimum is better). The descriptive statistics of change from baseline (CFB) in PANSS score at week 6 (W6) and week 12 (W12) are presented.
W6-Number of participants analyzed:79,74,67,71,154
Group
Value
95% CI
BI 409306 - 10 Milligram
-0.39
± 3.677
BI 409306 - 25 Milligram
-0.22
± 3.262
BI 409306 - 50 Milligram
-0.31
± 3.759
BI 409306 - 100 Milligram
-0.79
± 3.497
Placebo
-0.99
± 3.954
W12-Number of participant analyzed:83,78,76,81,157
Group
Value
95% CI
BI 409306 - 10 Milligram
-1.36
± 3.039
BI 409306 - 25 Milligram
-0.79
± 3.277
BI 409306 - 50 Milligram
-0.68
± 4.253
BI 409306 - 100 Milligram
-0.38
± 3.587
Placebo
-0.76
± 4.007
Adverse events — posted to ClinicalTrials.gov
Time frame: From first drug administration until 4 weeks after the last drug administration, up to 16 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
· Phase 3
· recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
· Phase 2
· recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
· recruiting
NCT06758414 — CBT-CP for Veterans With SMI
· NA
· recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis
· NA
· recruiting
Other Boehringer Ingelheim trials
Trials by the same sponsor.
NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection
· not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a
· not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I
· Phase 3
· not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants
· Phase 1
· not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
· Phase 3
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 19 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02281773.